NovoCure (BMV:NVCR N) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

NVCR N Panoramica delle azioni

An oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally.

Informazioni sull'azienda

NVCR N analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	1/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 7.1% all'anno

Analisi del rischio

Si prevede che gli utili diminuiranno in media di 5% all'anno per i prossimi 3 anni

Le azioni sono altamente illiquide

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

NovoCure Limited Concorrenti

Shinva Medical InstrumentLtd

SHSE:600587

CN¥11.6b

Fukuda Denshi

TSE:6960

JP¥222.0b

MeHow Innovative

SZSE:301363

CN¥13.9b

Integra LifeSciences Holdings

NasdaqGS:IART

US$1.4b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per NovoCure
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$275.39
Massimo di 52 settimane	US$2,140.47
Minimo di 52 settimane	US$275.39
Beta	0.52
1Variazione di 1 mese	0%
Variazione a 3 mesi	n/a
Variazione di 1 anno	n/a
3Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	-86.68%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	NVCR N	MX Medical Equipment	MX Mercato
7D	0%	0%	0%
1Y	n/a	0%	0%

Ritorno vs Industria: Dati insufficienti per determinare come si è comportato NVCR N rispetto al settore MX Medical Equipment.

Rendimento vs Mercato: Dati insufficienti per determinare la performance di NVCR N rispetto al mercato MX.

Volatilità dei prezzi

Is NVCR N's price volatile compared to industry and market?
NVCR N volatility
NVCR N Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Prezzo delle azioni stabile: NVCR N non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di NVCR N nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2000	1,320	Asaf Danziger	www.novocure.com

NovoCure Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di NovoCure con la sua capitalizzazione di mercato?
NVCR N statistiche fondamentali
Capitalizzazione di mercato	Mex$27.09b
Guadagni(TTM)	-Mex$3.35b
Ricavi(TTM)	Mex$8.56b

3.2x

Rapporto P/S

-8.1x

Rapporto P/E

NVCR N è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
NVCR N Conto economico (TTM)
Ricavi	US$503.98m
Costo del fatturato	US$124.00m
Profitto lordo	US$379.98m
Altre spese	US$577.25m
Guadagni	-US$197.27m

Ultimi guadagni dichiarati

Sep 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.85
Margine lordo	75.40%
Margine di profitto netto	-39.14%
Rapporto debito/patrimonio netto	144.3%

Come si è comportato NVCR N nel lungo periodo?

Vedi performance storica e confronto

NVCR N Panoramica delle azioni

Premi

Analisi del rischio

NovoCure Limited Concorrenti

SHSE:600587

CN¥11.6b

TSE:6960

JP¥222.0b

SZSE:301363

CN¥13.9b

NasdaqGS:IART

US$1.4b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Novocure Announces CEO Changes, Effective January 1, 2025

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index

NovoCure Limited to Report Q2, 2024 Results on Jul 25, 2024

Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial

Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany

NovoCure Limited announced that it expects to receive $400 million in funding

Recent updates

Novocure Announces CEO Changes, Effective January 1, 2025

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index

NovoCure Limited to Report Q2, 2024 Results on Jul 25, 2024

Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial

Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

NovoCure Limited Announces Executive Changes

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD)

Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

Chief Financial Officer recently sold Mex$589k worth of stock

Second quarter 2023 earnings released: US$0.54 loss per share (vs US$0.23 loss in 2Q 2022)

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Chief Operating Officer recently sold Mex$35m worth of stock

Chief Human Resources Officer recently sold Mex$383k worth of stock

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.56 loss in FY 2021)

Insufficient new directors

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

Novocure Announces Executive Changes

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Insufficient new directors

Insufficient new directors

Third quarter 2022 earnings released: US$0.25 loss per share (vs US$0.13 loss in 3Q 2021)

Insufficient new directors

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting

NovoCure Limited to Report Q3, 2022 Results on Oct 27, 2022

Insufficient new directors

Executive Chairman recently sold Mex$1.2m worth of stock

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.14 loss in 2Q 2021)

Insufficient new directors

NovoCure Limited to Report Q2, 2022 Results on Jul 28, 2022

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Now 20% undervalued after recent price drop

Chief Medical Officer recently sold Mex$5.4m worth of stock

Insufficient new directors

NovoCure Limited, Annual General Meeting, Jun 08, 2022

NovoCure Limited to Report Q1, 2022 Results on Apr 28, 2022

General Counsel recently sold Mex$4.6m worth of stock

Insufficient new directors

Novocure Announces Resignation of Todd Longsworth as General Counsel

Insufficient new directors

President recently bought Mex$11m worth of stock

Insufficient new directors

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

NovoCure Limited Riepilogo dei fondamenti